CRISPR Therapeutics AG (NASDAQ:CRSP) traded at $103.96 at last check on Friday, Nov 13, making an upward move of 2.15% on its previous day’s price.

Looking at the stock we see that its previous close was $101.77 and the beta (5Y monthly) reads 2.2 with the day’s price range being $101.70 – 105.55. The company has a 12-month trailing PE ratio of 0. In terms of its 52-week price range, CRSP has a high of $111.9 and a low of $32.3. The company’s stock has gained about 4.07% over that past 30 days.

CRISPR has a market cap of $7.39 Billion and is expected to release its quarterly earnings report on Feb 10, 2021- Feb 15, 2021. With its Forward Dividend at 0 and a yield of 0%, the company’s investors could be worried for the CRSP stock to lose ahead of the earnings release. Estimates by analysts give the company expected earnings per share (EPS) of -$1.27, with the EPS growth for the year declined at -$5.02 for 2020 and -$5.28 for next year. These figures represent -5.29% and at 0.05% growth in EPS for the two years respectively.

On the other hand, looking at the outlook for the CRSP stock, short term indicators assign the stock an average of 100% Buy, while medium term indicators assign it an average of 100% Buy. Long term indicators on average place the stock in the category of 100% Buy.

Based on estimates by 19 analysts where scores have ranged from 1.00 for a strong buy to 5.00 for a strong sell, 5 have rated the CRISPR Therapeutics AG (CRSP) stock as a Hold, while 11 rate it as a Buy. 1 analysts rate it as outperform while none of them rated it as underperform, whereas 2 suggests the stock as a Sell. The stock has an overall rating of Overweight and investors could take advantage and scoop up stock of the company.

Looking further, we note that the PEG ratio for the CRSP stock currently stands at 0, and the current price level is 6.64% off its SMA20 and 13.42% from its 50-day simple moving average. The RSI (14) is pointing at 58.97 while the volatility over the past week is 4.87% and jumps to 6.45% over the past one month. The beta value is 2.2, while the average true range (ATR) is currently pointing at 6.34. The average price target for the stock over the next 12 months is $102.63, with the estimates having a low of $45 and a high of $140. These price ends are -56.71% and +34.67% off the current price level respectively, although investors could be excited at the prospect of a +5.33% if the CRSP share price touches on the median price of $109.5.

Let’s briefly compare CRISPR (CRSP) stock to its peers. We find that today’s price change of +2.15% and +88.81% over the past 12 months for CRSP betters that of Bristol-Myers Squibb Company (BMY), which has seen its stock price rise 1.39% in the latest trading session and is +8.73% over the last one year. Another of its peers Amgen Inc (AMGN) has climbed 0.09% today, and is +8.63% up over the past year, while Gilead Sciences Inc (GILD) is also up 2.15% yet its price remains in the green at 88.81% over the same period. Bristol-Myers has a P/E ratio of 0 compared to CRISPR’s 0 and Amgen’s 19.14. In contrast to these companies, both the S&P 500 Index and the Dow Jones Industrial are today at 1.36% and 1.37%, respectively, in early deals.

Coming back to CRISPR Therapeutics AG (NASDAQ:CRSP), we note that the average 3-month trading volume was 975.16 Million, while that of the preceding 10-day period stands at 815.02 Million. Current shares outstanding are 70.65 Million.

According to data from Thomson Reuters, insiders hold 13.8% of the company’s shares while institutions hold 78.6%. The data shows that short shares as of October 29, 2020, stood at 6.33 Million at a short ratio of 4.83. This represents a 8.96% Short interest in Shares outstanding on October 29, 2020. Shares short rose in October from the previous month at 4.81 Million. Investors should be excited about this stock as its upside potential is great, with today’s price pushing the stock +70.69% up in year-to-date price movement.



Source link